Use of Lecanemab for Patients With Cardiovascular Disease
JAMA · 2024
DOI: 10.1001/jama.2024.2991 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von Darae Ko und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Alzheimer Disease, Antibodies, Monoclonal, Humanized, Cardiovascular Diseases, Cognitive Dysfunction. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIA NIH HHS.
Abstract (Originalsprache)
This Viewpoint discusses lecanemab use and the risk of cerebral macrohemorrhage for patients with mild cognitive impairment or early dementia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts.
- Section of Cardiovascular Medicine, Boston Medical Center, Boston, Massachusetts.
- Center for Aging and Serious Illness and Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
Förderung
- NHLBI NIH HHS
- NIA NIH HHS
Zitieren
APA
Ko, D., Pascual-Leone, A., & Shah, S. J. (2024). Use of Lecanemab for Patients With Cardiovascular Disease. JAMA. https://doi.org/10.1001/jama.2024.2991
Vancouver
Ko D, Pascual-Leone A, Shah SJ. Use of Lecanemab for Patients With Cardiovascular Disease. JAMA. 2024. doi:10.1001/jama.2024.2991
BibTeX
@article{Ko2024,
author = {Ko, Darae and Pascual-Leone, Alvaro and Shah, Sachin J},
title = {Use of Lecanemab for Patients With Cardiovascular Disease},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.2991}
}
EUVIMED